Full Press Release Details
Tiziana Appoints Dr. Kevin Schutz as Vice-President
of Regulatory Affairs
NEW YORK & LONDON, June 21, 2021 - Tiziana
Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology
company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment
of Dr. Kevin Schutz, PharmD, as Vice-President of Regulatory Affairs. Dr. Schutz will lead regulatory interactions related to clinical
studies in the United States, Europe and Asian countries.
Dr. Schutz has over 19 years of pharmaceutical
industry experience including 14 years of Regulatory Affairs experience. He has focused on disease indications with high unmet medical
needs, in Neurology (including multiple sclerosis), Pulmonology (including infectious disease), and other potential disease indications,
which the Company is currently developing products for or is planning to pursue. Specifically, Foralumab (an intranasally delivered, next
generation, fully human anti-CD3 monoclonal antibody) for Secondary Progressive Multiple Sclerosis (SPMS) and COVID-19 with Pulmonary
Inflammation as lead indications.
"Dr. Schutz brings extensive hands-on experience working with
regulatory agencies including the FDA (USA), EMA (Europe), and PMDA (Japan), among others. His background will greatly strengthen Tiziana's
global development capabilities in regions where the Company is actively pursuing clinical development. We are pleased to have him on
our team to lead this important role in global development of our pipeline" commented Dr. Neil Graham, Chief Medical Officer of
Tiziana Life Sciences
"I am excited to join the Tiziana team to further the development
of products which aim to help patients manage diseases with an unmet medical need. Tiziana's lead pipeline candidate, Foralumab,
is promising with multiple potential indications in multiple sclerosis and pulmonary diseases and I look forward to contributing to its
development" said Dr. Schutz.
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA,
LSE: TILS) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease
in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab
in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody
in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases,
such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin
6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.
Forward-Looking Statements
Certain statements made in this announcement are
forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,' expects,' intends,' plans,'
believes,' 'seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond
the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted
in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance
on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake
any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated
events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further enquiries:
Tiziana Life Sciences plc